Prostate cancer

44 trials 20 recruiting MedDRA PT
44 Registered trials
20 Recruiting
32 Unique sponsors
44 Unique IMPs
27 Commercial trials
Drug classes (ATC)
— ATC code not specified 21
L Oncology (ATC L) 16
V Various (ATC V) 5
H Endocrinology (ATC H) 2
S Ophthalmology/ENT (ATC S) 1
N Neurology/Psychiatry (ATC N) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 32 substances
PARP inhibitor 3 substances
Taxane 2 substances
Antibody-drug conjugate (ADC) 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (chimeric) 1 substance
Corticosteroid 1 substance
Alkylating agent 1 substance
Radiopharmaceutical 1 substance
Phase III: 20 Phase II/III: 1 Phase II: 10 Phase I/II: 4 Phase I: 5 Phase I (Other): 1 Phase I (First in Human): 3

Filter these 44 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 44 trials

Phase III

20 trials
  • A.C.O.M. Advanced Center Oncology Macerata S.r.l. Commercial
    COPPER (64CU) CHLORIDE; FLUOROCHOLINE (18F)
    2025-520861-29-00 1 country n=285
    Pending
  • A.C.O.M. Advanced Center Oncology Macerata S.r.l. Commercial
    COPPER (64CU) CHLORIDE
    2025-520868-17-00 1 country n=138
    Pending
  • Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH Commercial
    (2S)-2-[[(1S)-1-CARBOXY-5-[[(2S)-2-[[4-[[[(2S)-4-CARBOXY-2-[[(2S)-4-CARBOXY-2-[(6-(18F)FLUORANYLPYRIDINE-3-CARBONYL)AMINO]BUTANOYL]AMINO]BUTANOYL]AMINO]METHYL]BENZOYL]AMINO]-3-NAPHTHALEN-2-YLPROPANOYL]AMINO]PENTYL]CARBAMOYLAMINO]PENTANEDIOIC ACID; (3S,10S,14S)-1-[4-[[(2S)-4-CARBOXY-2-[(2S)-4-CARBOXY-2-(6-[18F] FLUOROPYRIDIN-3-AMIDO)BUTANAMIDO]BUTANAMIDO]METHYL]PHENYL]-3-[(NAPHTHALEN-2-YL)METHYL]-1,4,12-TRIOXO-2,5,11,13-TETRAAZAHEXADECANE-10,14,16-TRICARBOXYLIC ACID
    2023-504026-19-01 5 countries 2024 n=355
    Recruiting
  • Amgen Inc. Commercial
    SILTUXIMAB; XALURITAMIG
    2024-513968-25-00 11 countries 2025 n=344
    Ended
  • Amgen Inc. Commercial
    SILTUXIMAB; XALURITAMIG
    2025-520555-89-00 9 countries 2025 n=297
    Recruiting
  • AstraZeneca AB Commercial
    CAPIVASERTIB; DOCETAXEL
    2023-504996-26-00 8 countries 2022 n=424
    Ended
  • AstraZeneca AB Commercial
    OLAPARIB
    2024-512982-15-00 12 countries 2021 n=94
    Recruiting
  • Curium US LLC Commercial
    64CU-PSMA I&T
    2024-512754-16-00 3 countries n=150
    Not authorised
  • Curium US LLC Commercial
    64CU-PSMA I&T
    2024-512754-16-01 3 countries n=150
    Ended
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial
    4-((3-((5,6-DIHYDRO-2-(TRIFLUOROMETHYL)(1,2,4)TRIAZOLO(1,5-A)PYRAZIN-7(8H)-YL)CARBONYL)-4-FLUOROPHENYL)METHYL)-1(2H)-PHTHALAZINONE; ABIRATERONE ACETATE; PREDNISONE
    2023-509396-16-00 6 countries 2021 n=136
    Ended
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial
    BICALUTAMIDE; GOSERELIN; REZVILUTAMIDE
    2024-515194-10-00 3 countries n=63
    Pending
  • Medivation Inc. Commercial
    ENZALUTAMIDE
    2024-513521-23-00 10 countries 2015 n=366
    Ended
  • Cancer Trials Ireland Academic
    DAROLUTAMIDE
    2024-514565-18-00 1 country 2021 n=36
    Ended
  • Cancer Trials Ireland Academic
    BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE; NILUTAMIDE
    2024-514808-13-00 3 countries 2015 n=79
    Ended
  • Cancer Trials Ireland Academic
    BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE
    2024-516137-13-00 1 country 2014 n=82
    Ended
  • Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi Academic
    IMP not specified
    2024-513450-30-00 3 countries 2017 n=476
    Ended
  • Region Vaesterbotten Academic
    GADOTERIC ACID; GLUCAGON; HYOSCINE BUTYLBROMIDE
    2022-501892-14-00 1 country 2024 n=20
    Recruiting
  • Unicancer Academic
    DAROLUTAMIDE
    2023-509787-15-00 2 countries 2025 n=450
    Recruiting
  • Unicancer Academic
    APALUTAMIDE
    2024-514829-36-00 1 country 2019 n=429
    Ended
  • Unicancer Academic
    CABAZITAXEL
    2024-517622-25-00 3 countries 2013 n=760
    Ended

Phase II/III

1 trial
  • Narodowe Centrum Badan Jadrowych Academic
    PSMA-T4
    2024-519358-35-00 1 country n=80
    Pending

Phase II

10 trials
  • Antev Limited Commercial
    TEVERELIX
    2023-509255-14-01 1 country n=44
    Pending
  • Astellas Pharma Global Development Inc. Commercial
    ABIRATERONE DECANOATE
    2024-517653-27-00 5 countries 2025 n=89
    Recruiting
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE
    2023-506618-29-00 6 countries 2021 n=10 Orphan
    Recruiting
  • Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial
    PEMBROLIZUMAB; SKB264
    2022-502654-14-00 4 countries 2023 n=101
    Recruiting
  • UroTrials GmbH Commercial
    BMS-986365
    2025-523672-23-00 1 country n=42
    Pending
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    RELUGOLIX
    2025-521170-33-00 1 country 2025 n=50
    Recruiting
  • Linac-Pet Scan Opco Limited Academic
    IMP not specified
    2024-510707-11-00 1 country 2024 n=30
    Recruiting
  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Academic
    LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
    2023-504912-13-00 1 country 2025 n=200
    Recruiting
  • Universitaet Muenster Academic
    APALUTAMIDE
    2024-511832-29-00 2 countries 2020 n=190
    Ended
  • Vychodoslovensky Onkologicky Ustav a.s. Academic
    APALUTAMIDE
    2024-517901-97-00 1 country 2023 n=48
    Ended

Phase I/II

4 trials
  • Curasight A/S Commercial
    64CU-DOTA-AE105
    2023-507111-35-00 3 countries 2024 n=168
    Recruiting
  • SpectraCure AB (publ) Commercial
    VERTEPORFIN
    2024-519658-35-00 1 country n=20
    Pending
  • Amsterdam UMC Stichting Academic
    DAROLUTAMIDE
    2025-520482-52-03 1 country n=32
    Pending
  • Universitaetsklinikum Essen AöR Academic
    LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
    2022-500838-28-00 1 country 2024 n=22
    Recruiting

Phase I

5 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    IMP not specified
    2025-521886-28-00 1 country 2026 n=15
    Recruiting
  • Duke Street Bio Limited Commercial
    IMP not specified
    2023-508805-26-00 4 countries 2024 n=101
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2023-504063-17-00 2 countries 2024 n=71
    Recruiting

Phase I (Other)

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2024-511965-13-00 1 country 2024 n=12
    Halted

Phase I (First in Human)

3 trials
  • AstraZeneca AB Commercial
    [11C]AZ14193391; 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; DATOPOTAMAB DERUXTECAN; PALACAPARIB; TEMOZOLOMIDE; TRASTUZUMAB DERUXTECAN
    2023-504984-17-00 2 countries 2022 n=176
    Recruiting
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    99MTC-EUK-(SO3)CY5-MAS3
    2023-505453-40-00 1 country n=13
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 3 Phase I (Other), Phase III 1
AstraZeneca AB Commercial 3 Phase III, Phase I (First in Human) 2
Cancer Trials Ireland Academic 3 Phase III 0
Unicancer Academic 3 Phase III 1
BeOne Medicines AG Commercial 2 Phase I 2
A.C.O.M. Advanced Center Oncology Macerata S.r.l. Commercial 2 Phase III 0
Curium US LLC Commercial 2 Phase III 0
Jiangsu Hengrui Pharmaceuticals Co. Ltd. Commercial 2 Phase III 0
Daiichi Sankyo Inc. Commercial 1 Phase I 1
Duke Street Bio Limited Commercial 1 Phase I 1
Janssen - Cilag International Commercial 1 Phase I 1
Antev Limited Commercial 1 Phase II 0
Astellas Pharma Global Development Inc. Commercial 1 Phase II 1
Glaxosmithkline Research & Development Limited Commercial 1 Phase II 1
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial 1 Phase II 1
UroTrials GmbH Commercial 1 Phase II 0
Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH Commercial 1 Phase III 1
Medivation Inc. Commercial 1 Phase III 0
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 1
Curasight A/S Commercial 1 Phase I/II 1
New trials by year
2019
1
2020
1
2021
4
2022
2
2023
2
2024
9
2025
7
2026
2
← All indication landscapes